HER2 drugs for Breast Cancer
4 tracked HER2 drugs in the Breast Cancer race. The class explanation lives on the HER2 page; the full indication pipeline across every mechanism is on the Breast Cancer page.
3 approved / phase 41 Phase 3
Head-to-head evidence: Trastuzumab Deruxtecan vs Trastuzumab rezetecan · Trastuzumab Deruxtecan vs Tucatinib · margetuximab vs Trastuzumab Deruxtecan · Trastuzumab rezetecan vs Tucatinib · margetuximab vs Tucatinib